JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer that has spread and cannot be removed by surgery.
- You have not had any previous cancer treatment for advanced lung cancer (like chemotherapy or targeted therapy).
- Your tumor has an EGFR sensitive mutation (a specific change in the gene that helps cancer grow).
- You are able to do your daily activities without help (ECOG performance status 0 or 1).
- Your blood counts, kidney, and liver function are within certain limits (your doctor will check these).
- You do not have other gene changes that could be treated with a different targeted drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
This trial studies a new targeted pill (JMT101) combined with another targeted pill (osimertinib) to see if it works better than standard chemotherapy for advanced lung cancer with an EGFR exon 20 insertion mutation. It might help if your cancer has this specific gene change.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This study tests a new drug (SYS6010) combined with an existing targeted therapy (osimertinib) for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than standard treatments and to find a safe dose.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Hear when a new Locally Advanced or Metastatic Non-squamous NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.